Evidence map›Paper›PMID 31410730›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.

Y Wang, Y Zhang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Y WangDepartment of Urologic Surgery, Yantai Affiliated Hospital of Binzhou Medical University, No. 717, Jinbu Street, Muping District, Yantai, Shandong, 264100, China. ylwang_med@126.com.ORCID http://orcid.org/0000-0001-5941-4054
Y ZhangOffice of Quality Assurance and Safety Management, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, China.
Binzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the prognostic role of interleukin-6 (IL-6) in renal cell carcinoma (RCC).

methodRelevant research articles were obtained from literature databases. Data were extracted from study reports which reported IL-6 levels in relevance to RCC prognosis and random-effects meta-analyses were performed to estimate IL-6 levels, percentage of patients with high IL-6 levels, and hazard/odds ratios between high and low IL-6 levels in survival outcomes.

results22 studies (1976 patients; age 59.9 years [95% confidence interval (CI) 58.0, 61.8]; 33% [95% CI 29, 36] females) were included. IL-6 levels in RCC patients ranged from 8.9 ± 13-193 ± 101 picograms per milliliter (pg/ml) which were higher than those of normal healthy individuals (mean difference 13.96 pg/ml [95% CI: 1.52, 26.40]; p = 0.03). Percentage of RCC patients with high IL-6 levels was 48.98% [95% CI 42.94, 55.03] and this rate was greater in advanced (51.73% [95% CI 45.94, 57.53]) than in local (40.75% [95% CI 26.23, 55.27]) RCC. Survival was longer in patients with low compared to high IL-6 levels (MD 9.65 months [95% CI 5.01, 14.29]; p < 0.0006 and hazard ratio 3.03 [95% CI 2.37, 3.70]). Treatment response rate was significantly higher in patients with low IL-6 than high IL-6 levels (odds ratio 5.11 [95% CI 2.21, 11.77]; p < 0.00001). There was a strong correlation between IL-6 and c-reactive protein levels (correlation coefficient 0.622 [95% CI 0.431, 0.760]; p = 0.00001).

conclusionIL-6 levels are much variable in RCC patients. High levels of IL-6 in RCC patients are associated with poor survival.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellFemaleHumansInterleukin-6Kidney NeoplasmsMaleMiddle AgedPrognosisSurvival AnalysisTreatment OutcomeBiomarkers, TumorIL6 protein, humanInterleukin-6Interleukin-6MetastasisPrognosisRenal cell carcinomaSurvival

Identifiers

PMID31410730
OpenAlexW2968153353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.